As the flurry of executive orders continues to flow from the White House, leaving in its wake chaos and confusion across the ...

In response to the news of reported layoffs at the U.S. FDA over the weekend, Advanced Medical Association president and CEO ...

Once high-flying Bluebird Bio Inc. has found a way out of its financial squeeze, as funds managed by global investment firms ...

Researchers from Columbia University Irving Medical Center and collaborators applied unbiased scRNA-seq to study Lepr ...

Gene therapy specialist Meiragtx Holdings plc is heading for its first marketing approval following the successful treatment ...

Roche Holding AG revealed plans to launch its sequencing by expansion technology next year, raising the possibility that ...

Approxima Srl raised €7.3 million (US$7.65 million) in the first close of its series A financing round for its tricuspid valve repair system which is based on reshaping the right ventricle.

Using ALK+ lung cancer patient-derived cell lines, researchers have performed phosphoproteomic screening and identified ...

A paper published in The Lancet showed that four out of four young children with Leber congenital amaurosis 4 retinal dystrophy due to a genetic deficiency of Aryl-hydrocarbon-interacting protein-like ...

Several Asia biotechs this week – including Innocare Pharma Ltd., Akeso Pharmaceuticals Inc., Sanbio Co. Ltd. and Ascletis Pharma Inc. – unveiled the start of new late-stage clinical trials or interim ...

Adcentrx Therapeutics Inc. and Adcentrx Therapeutics Shanghai Co. Ltd. have disclosed antibody-drug conjugates comprising a monoclonal antibody covalently bound to a cytotoxic drug through a linker.

Photys Therapeutics Inc. has signed a license agreement with Hangzhou Polymed Biopharmaceuticals Inc. for HPB-143, a phase I-ready IRAK-4 degrader. IRAK-4 degradation offers potential to treat various ...